Tagged with AZ

LatAm Adium is one of Latin America’s most expansive pharmaceutical groups, operating across 18 countries with a workforce of 7,000 employees. The organisation has unified its brand identity across the region whilst establishing world-class infrastructure and capabilities spanning oncology, rare diseases, and speciality therapeutics. The company´s strategic vision centres on positioning…

Brazil Sylvester Feddes, Country President of Novartis Brazil, outlines the country’s rise as a top global market driven by strong public-private healthcare infrastructure and vast unmet needs. With nearly 100 active clinical trials and major launches ahead across cardiovascular-renal-metabolic, immunology, neurology and oncology, Novartis is pairing scientific innovation with new access…

Brazil As one of Brazil’s leading pharmaceutical powerhouses, CIMED has redefined what it means to be both national and innovative. Built on a fully verticalised model that spans from R&D to direct distribution, the family-owned company has transformed the pharmacy landscape while empowering thousands of independent retailers across the country. Now,…

Denmark Not only can Denmark lay claim to some major life science inventions – from the design of the world’s first ever insulin pen and disposable ostomy pouch to breakthroughs in fundamental discovery such as the development of the Gram Stain as an essential methodology for classifying bacteria – but it…

Denmark Despite its diminutive size, Denmark boasts a world-renowned healthcare and life science industry containing both household pharma giants as well as a robust network of academia, a host of niche service providers, and a growing throng of biotech start-ups. And with life science exports surpassing EUR 23 billion last year…

Denmark Making Life Sciences Strategic The super-sized contribution of the life sciences sector to Denmark’s national economy can hardly be overstated. With over 100,000 professionals currently engaged in biotech and pharmaceuticals across the country, Denmark already ranks as one of the European Union member states with the largest proportion of the…

Brazil As Latin America’s largest pharma market, worth USD 62 billion in 2024, Brazil is retooling its industry to meet new demands. Driven by changing demographics, chronic disease burdens, and the growing expectations of a more affluent middle class, the Brazilian government is prioritising local production in key therapeutic niches while…

Alexion Dana Vigier, Regional Vice President at Alexion, AstraZeneca Rare Disease blends clinical training as a French general practitioner with broad pharmaceutical leadership experience. Formerly President of the French Pharma Association in Oncology and a Global Franchise leader at AstraZeneca, she now oversees Alexion’s operations across Central and Northern Europe, including…

Global The CGT field is undergoing a critical transformation from boom to thoughtful reset. While early enthusiasm brought a rush of investment and regulatory attention, the sector is now refining its ambitions, weeding out unviable approaches, and laying the foundations for long-term impact. Companies, regulators, and healthcare systems are rethinking what…

Brazil Brazil’s pharmaceutical sector is undergoing a quiet but significant transformation. Once dominated by multinationals and focused largely on generics, a group of leading domestic players is now charting a different course, towards innovation, manufacturing sovereignty, and strategic influence. Speaking on behalf of Grupo FarmaBrasil, a coalition of the country’s top…

Global Whether in the corridors of the FDA or the fast-evolving frameworks of ANVISA in Brazil, regulators around the world are undergoing a quiet revolution. While mature markets like the US and Europe double down on digitalisation and real-world evidence, emerging players like Brazil and China are accelerating access and joining…

USA The latest stories from healthcare and the life sciences in the US. The FDA names Stanford’s George Tidmarsh as the new head of CDER; AstraZeneca commits USD 50 billion to new US manufacturing and R&D projects; Moderna cancels its planned mRNA facility in Japan; Sarepta refuses to halt Elevidys shipments…